Norgen launches 6 novel kits for simple isolation of NA from blood, plasma, serum, urine

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 6 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA. Data from comparisons of these kits with similar kits on the market clearly indicates that NBC's kits yield significantly more diverse cfcRNA, owing to the fact that NBC kits use a proprietary resin technology that has the ability to bind all RNA sequences irrespective of size or GC content. Moreover, these new kits are both rapid and robust. The sensitivity and speed of these novel kits make them very powerful tools for a number of applications including the sensitive detection of tumor biomarkers and viruses, microRNA detection by PCR, quantitative PCR, RT-PCR, microarrays, Next Gen Sequencing, etc.

NBC's blood/plasma/serum and urine kits utilize a convenient spin column format for NA purification, and both fresh and frozen samples can be processed. In particular, the circulating NA kits provide a major advantage over other available kits in that they isolate significantly more diverse cfcRNA than any other technology on the market. Circulating NA present in 200 mL plasma inputs (or 3.0 mL of urine inputs) are concentrated into final elution volumes of 10 mL that can be used directly in sensitive downstream applications, as the kits completely remove all contaminants and inhibitors. Novel Kits with similar specifications to process up to 5 mL of plasma/serum (and up to 50ml of urine) specimens will be launched during the next couple of months.

"We are confident that this basket of new kits represents a very exciting addition to our line of high quality products. These kits capture significantly more diverse cfcRNA (microRNA) from a given specimen than any other kit on the market, and therefore these kits are a must for scientists who diligently screened (or currently screening) plasma yet are missing a significant number of targets or useful biomarkers. Re-examination of these specimens with our novel kits would allow these scientists to detect all those microRNAs that were missed in the previous screenings. We also offer contract R&D to re-isolate cfcRNA and cfcDNA from these same specimens. Our mission is to accelerate discovery by bringing to market innovative Best-in-Class sample preparation products that can be used in research as well as in MDx applications." said Dr. Haj-Ahmad, President & CEO of NBC.



Norgen Biotek Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New approach to COVID-19 immune profiling using blood-based machine learning